# Safety and Immunogenicity of Trivalent Subunit Inactivated Flu Vaccine Administered to Healthy Children and Adolescents 3 to 17 Years of Age

> **NCT01209780** · PHASE3 · COMPLETED · sponsor: **Novartis Vaccines** · enrollment: 3116 (actual)

## Conditions studied

- Seasonal Influenza

## Interventions

- **BIOLOGICAL:** TIV
- **BIOLOGICAL:** TIVf
- **BIOLOGICAL:** Comparator TIV

## Key facts

- **NCT ID:** NCT01209780
- **Lead sponsor:** Novartis Vaccines
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-09
- **Primary completion:** 2011-03
- **Final completion:** 2011-09
- **Target enrollment:** 3116 (ACTUAL)
- **Last updated:** 2014-03-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01209780

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01209780, "Safety and Immunogenicity of Trivalent Subunit Inactivated Flu Vaccine Administered to Healthy Children and Adolescents 3 to 17 Years of Age". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT01209780. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*